| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | MANDALMED, INC. | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43AR084638 | Cell-based Gene Therapy for MPS IVA | 000 | 1 | NIH | 6/24/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $306,872 ) |
| | 2024 | 2024 | MANDALMED, INC. | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43AR084638 | Cell-based Gene Therapy for MPS IVA | 000 | 1 | NIH | 7/23/2024 | $306,872 |
|
| Issue Date FY: 2022 ( Subtotal = -$1 ) |
| | 2022 | 2018 | MANDALMED INC | 665 3RD ST | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43DK107285 | Biologic Inhibitor of Galectin-3 for Liver Fibrosis | 000 | 1 | NIH | 2/15/2022 | -$1 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2018 | MANDALMED, INC. | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 000 | 3 | NIH | 11/8/2020 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $0 ) |
| | 2020 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43DK107285 | Biologic Inhibitor of Galectin-3 for Liver Fibrosis | 000 | 1 | NIH | 8/19/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43DK107285 | Biologic Inhibitor of Galectin-3 for Liver Fibrosis | 000 | 1 | NIH | 1/10/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,493,136 ) |
| | 2018 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 004 | 3 | NIH | 4/4/2018 | $6,636 |
| | 2018 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R43DK107285 | Biologic Inhibitor of Galectin-3 for Liver Fibrosis | 000 | 1 | NIH | 9/20/2018 | $299,900 |
| | 2018 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 002 | 3 | NIH | 3/6/2018 | $1,054,447 |
| | 2018 | 2018 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 005 | 3 | NIH | 8/17/2018 | $131,530 |
| | 2018 | 2017 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 001 | 2 | NIH | 10/18/2017 | $20,718 |
| | 2018 | 2017 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 003 | 2 | NIH | 4/4/2018 | $623 |
| | 2018 | 2016 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 000 | 1 | NIH | 10/18/2017 | -$20,718 |
|
| Issue Date FY: 2017 ( Subtotal = $807,969 ) |
| | 2017 | 2017 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 001 | 2 | NIH | 4/10/2017 | $807,969 |
| | 2017 | 2016 | MANDALMED INC | 665 3RD ST STE 250 | SAN FRANCISCO | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 000 | 1 | NIH | 3/29/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $224,734 ) |
| | 2016 | 2016 | MANDALMED, INC | 665 3rd St Ste 250 | San Francisco | CA | 94107-1953 | SAN FRANCISCO | USA | R44AG054386 | Inhibition of Galectin-3 for Therapy of Remodeling After Myocardial Infarction | 000 | 1 | NIH | 8/15/2016 | $224,734 |
|
| Issue Date FY: 2013 ( Subtotal = $299,958 ) |
| | 2013 | 2013 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43HL120645 | PROTEIN INHIBITOR OF GALECTIN-3 TO LIMIT FIBROSIS AFTER MYOCARDIAL INFARCTION | 001 | 1 | NIH | 9/4/2013 | $0 |
| | 2013 | 2013 | MANDALMED, INC | 665 3rd St Ste 250 | San Francisco | CA | 94107-1953 | SAN FRANCISCO | USA | R43HL120645 | PROTEIN INHIBITOR OF GALECTIN-3 TO LIMIT FIBROSIS AFTER MYOCARDIAL INFARCTION | 000 | 1 | NIH | 8/26/2013 | $299,958 |
|
| Issue Date FY: 2011 ( Subtotal = $250,000 ) |
| | 2011 | 2011 | MANDALMED, INC | 665 3rd St Ste 250 | San Francisco | CA | 94107-1953 | SAN FRANCISCO | USA | R43ES019824 | MODEL OF THE HUMAN TESTIS FOR REPRODUCTIVE TOXICOLOGY | 000 | 1 | NIH | 8/21/2011 | $250,000 |
| | 2011 | 2008 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43CA135862 | PRECLINICAL TESTING OF GALECTIN-3C FOR MULTIPLE MYELOMA | 000 | 1 | NIH | 11/30/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $0 ) |
| | 2009 | 2008 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43CA135862 | PRECLINICAL TESTING OF GALECTIN-3C FOR MULTIPLE MYELOMA | 000 | 1 | NIH | 5/4/2009 | $0 |
|
| Issue Date FY: 2008 ( Subtotal = $363,936 ) |
| | 2008 | 2008 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43CA135862 | PRECLINICAL TESTING OF GALECTIN-3C FOR MULTIPLE MYELOMA | 000 | 1 | NIH | 9/15/2008 | $363,936 |
|
| Issue Date FY: 2007 ( Subtotal = $255,200 ) |
| | 2007 | 2007 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43HD056620 | HUMAN SERTOLI CELL MODEL FOR STUDY OF MALE REPRODUCTIVE FUNCTION AND TOXICITY | 000 | 1 | NIH | 8/10/2007 | $255,200 |
|
| Issue Date FY: 2005 ( Subtotal = $134,000 ) |
| | 2005 | 2005 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43DK069128 | NO-DONOR/SOD-MIMETICS FOR DIABETIC NEPHROPATHY | 000 | 1 | NIH | 1/28/2005 | $134,000 |
|
| Issue Date FY: 2004 ( Subtotal = $375,427 ) |
| | 2004 | 2004 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R44HD042333 | NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY | 000 | 3 | NIH | 6/30/2004 | $375,427 |
|
| Issue Date FY: 2003 ( Subtotal = $374,553 ) |
| | 2003 | 2003 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R44HD042333 | NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY | 000 | 2 | NIH | 8/7/2003 | $374,553 |
|
| Issue Date FY: 2002 ( Subtotal = $411,190 ) |
| | 2002 | 2002 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43HD042333 | NOVEL EX VIVO GENE THERAPY FOR SPINAL CORD INJURY | 000 | 1 | NIH | 3/29/2002 | $155,695 |
| | 2002 | 2002 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43CA092801 | NOVEL TREATMENT FOR BREAST CANCER: TRUNCATED GALECTIN-3 | 000 | 2 | NIH | 6/1/2002 | $255,495 |
|
| Issue Date FY: 2001 ( Subtotal = $236,893 ) |
| | 2001 | 2001 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43CA092801 | NOVEL TREATMENT FOR BREAST CANCER: TRUNCATED GALECTIN-3 | 000 | 1 | NIH | 7/10/2001 | $236,893 |
|
| Issue Date FY: 2000 ( Subtotal = $191,417 ) (Continued on the next page) |
| | 2000 | 2000 | MANDALMED, INC | 2645 OCEAN AVENUE SUITE 302 | SAN FRANCISCO | CA | 94132 | SAN FRANCISCO | USA | R43DK057356 | PLACENTAL CELLS FOR PROTECTION OF IMPLANTED B ISLETS | 000 | 1 | NIH | 7/17/2000 | $142,130 |
|
